Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation

Avinash K. Shetty, Mary A. Winter

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

In the past 3 decades, the number of immunocompromised children has increased steadily because of dramatic improvement in survival rates in certain malignancies as a result of intensive curative treatment regimens and an increase in the number of children undergoing life-saving hematopoietic stem cell transplantation (HSCT). Children receiving immunosuppressive therapy for cancer, as well as HSCT recipients, will benefit from vaccination but warrant close evaluation for a variety of reasons, such as the risk of developing severe infections, serious adverse events following certain vaccines, and decreased vaccine efficacy caused by poor immune response to vaccination. Various professional organizations have published vaccination guidelines for immunocompromised patients. Given their heterogeneity, recommendations for the immunization of immunocompromised patients may not be universally applicable. The safety of many commonly used vaccines has not been established in immunocompromised children. In addition, no large-scale vaccine studies have evaluated the clinical outcome of disease prevention in this population. All killed vaccines are generally safe, while live vaccines may be administered to immunocompromised children in select circumstances, depending on the degree of altered immunocompetence and the underlying primary condition. Healthcare providers should be knowledgeable about the indications, contraindications, and precautions for vaccine administration in immunocompromised patients. To protect immunocompromised patients, all family, household contacts, and healthcare workers should also be immunized with all routinely recommended vaccines. Pediatricians play a crucial role in identifying and effectively communicating the risks and benefits of vaccines to immunocompromised patients and their parents.

Original languageEnglish
Pages (from-to)228-243
Number of pages16
JournalOchsner Journal
Volume12
Issue number3
Publication statusPublished - 26-09-2012
Externally publishedYes

Fingerprint

Neoplastic Stem Cells
Hematopoietic Stem Cell Transplantation
Immunosuppressive Agents
Immunization
Vaccines
Immunocompromised Host
Vaccination
Therapeutics
Immunocompetence
Inactivated Vaccines
Health Personnel
Survival Rate
Parents
Guidelines
Delivery of Health Care
Safety
Infection

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{35ca96f8d8e647c495c321ccfd6cdd36,
title = "Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation",
abstract = "In the past 3 decades, the number of immunocompromised children has increased steadily because of dramatic improvement in survival rates in certain malignancies as a result of intensive curative treatment regimens and an increase in the number of children undergoing life-saving hematopoietic stem cell transplantation (HSCT). Children receiving immunosuppressive therapy for cancer, as well as HSCT recipients, will benefit from vaccination but warrant close evaluation for a variety of reasons, such as the risk of developing severe infections, serious adverse events following certain vaccines, and decreased vaccine efficacy caused by poor immune response to vaccination. Various professional organizations have published vaccination guidelines for immunocompromised patients. Given their heterogeneity, recommendations for the immunization of immunocompromised patients may not be universally applicable. The safety of many commonly used vaccines has not been established in immunocompromised children. In addition, no large-scale vaccine studies have evaluated the clinical outcome of disease prevention in this population. All killed vaccines are generally safe, while live vaccines may be administered to immunocompromised children in select circumstances, depending on the degree of altered immunocompetence and the underlying primary condition. Healthcare providers should be knowledgeable about the indications, contraindications, and precautions for vaccine administration in immunocompromised patients. To protect immunocompromised patients, all family, household contacts, and healthcare workers should also be immunized with all routinely recommended vaccines. Pediatricians play a crucial role in identifying and effectively communicating the risks and benefits of vaccines to immunocompromised patients and their parents.",
author = "Shetty, {Avinash K.} and Winter, {Mary A.}",
year = "2012",
month = "9",
day = "26",
language = "English",
volume = "12",
pages = "228--243",
journal = "Ochsner Journal",
issn = "1524-5012",
publisher = "Ochsner Clinic",
number = "3",

}

Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation. / Shetty, Avinash K.; Winter, Mary A.

In: Ochsner Journal, Vol. 12, No. 3, 26.09.2012, p. 228-243.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation

AU - Shetty, Avinash K.

AU - Winter, Mary A.

PY - 2012/9/26

Y1 - 2012/9/26

N2 - In the past 3 decades, the number of immunocompromised children has increased steadily because of dramatic improvement in survival rates in certain malignancies as a result of intensive curative treatment regimens and an increase in the number of children undergoing life-saving hematopoietic stem cell transplantation (HSCT). Children receiving immunosuppressive therapy for cancer, as well as HSCT recipients, will benefit from vaccination but warrant close evaluation for a variety of reasons, such as the risk of developing severe infections, serious adverse events following certain vaccines, and decreased vaccine efficacy caused by poor immune response to vaccination. Various professional organizations have published vaccination guidelines for immunocompromised patients. Given their heterogeneity, recommendations for the immunization of immunocompromised patients may not be universally applicable. The safety of many commonly used vaccines has not been established in immunocompromised children. In addition, no large-scale vaccine studies have evaluated the clinical outcome of disease prevention in this population. All killed vaccines are generally safe, while live vaccines may be administered to immunocompromised children in select circumstances, depending on the degree of altered immunocompetence and the underlying primary condition. Healthcare providers should be knowledgeable about the indications, contraindications, and precautions for vaccine administration in immunocompromised patients. To protect immunocompromised patients, all family, household contacts, and healthcare workers should also be immunized with all routinely recommended vaccines. Pediatricians play a crucial role in identifying and effectively communicating the risks and benefits of vaccines to immunocompromised patients and their parents.

AB - In the past 3 decades, the number of immunocompromised children has increased steadily because of dramatic improvement in survival rates in certain malignancies as a result of intensive curative treatment regimens and an increase in the number of children undergoing life-saving hematopoietic stem cell transplantation (HSCT). Children receiving immunosuppressive therapy for cancer, as well as HSCT recipients, will benefit from vaccination but warrant close evaluation for a variety of reasons, such as the risk of developing severe infections, serious adverse events following certain vaccines, and decreased vaccine efficacy caused by poor immune response to vaccination. Various professional organizations have published vaccination guidelines for immunocompromised patients. Given their heterogeneity, recommendations for the immunization of immunocompromised patients may not be universally applicable. The safety of many commonly used vaccines has not been established in immunocompromised children. In addition, no large-scale vaccine studies have evaluated the clinical outcome of disease prevention in this population. All killed vaccines are generally safe, while live vaccines may be administered to immunocompromised children in select circumstances, depending on the degree of altered immunocompetence and the underlying primary condition. Healthcare providers should be knowledgeable about the indications, contraindications, and precautions for vaccine administration in immunocompromised patients. To protect immunocompromised patients, all family, household contacts, and healthcare workers should also be immunized with all routinely recommended vaccines. Pediatricians play a crucial role in identifying and effectively communicating the risks and benefits of vaccines to immunocompromised patients and their parents.

UR - http://www.scopus.com/inward/record.url?scp=84866519295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866519295&partnerID=8YFLogxK

M3 - Review article

VL - 12

SP - 228

EP - 243

JO - Ochsner Journal

JF - Ochsner Journal

SN - 1524-5012

IS - 3

ER -